Bharat Biotech on Thursday said that its Covid-19 vaccine, Covaxin, has maintained an impeccable safety profile, devoid of any vaccine-associated incidents such as blood clots, thrombocytopenia, TTS, VITT, pericarditis, myocarditis, among others. The company added that the development of this vaccine was done meticulously and keeping primary focus on the safety aspect followed by efficacy.
Amid concerns coming from some quarters on the safety of Covid vaccines, especially after AstraZeneca announced that it had identified a rare side effect of blood clotting and low platelet count associated with its Covid vaccine, Covishield, Bharat Biotech took the initiative to reassure the public. Additionally, apart from the adverse events, the rare side effect of blood clotting and low platelet count associated with Covishield, developed by Oxford University researchers and manufactured by Serum Institute in Pune, saw widespread administration with some 1.75 billion doses being administered in India.
Bharat Biotech declared Covaxin as the only Covid-19 vaccine within India's immunization program to have been tested for efficacy within the country. "Covaxin was subjected to evaluation involving over 27,000 subjects during its licensure process. It received licensure under restricted use in clinical trial mode, enabling detailed safety reporting for several hundred thousand subjects," the vaccine manufacturer stated.
Apart from this, the safety of Covaxin was also evaluated by the Ministry of Health, with ongoing pharmacovigilance monitoring continuing throughout its product life cycle. "Comprehensive studies and safety follow-up activities have consistently demonstrated Covaxin's exemplary safety record, devoid of any vaccine-associated incidents such as blood clots, thrombocytopenia, TTS, VITT, pericarditis, myocarditis, among others," Bharat Biotech added.
As far as this is concerned, the company insisted that, while the efficacy of Covid-19 vaccines may vary, the safety of the vaccine should never be compromised, for which it tries to prioritize safety in the development of the.
Read also | Adani Ports & SEZ Attains AAA Rating Milestone, Pioneering Industry Standards
Read also | India's Bold Stance on Russian Oil Procurement Results in $8 Billion Import Bill Savings
